Loading search results
Sponsor study identifier
interventional
120
1 country
1
Study Start
March 18, 2026
Actual (reported)Primary Completion
March 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
March 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
The goal of this clinical trial is to learn if a short course of a potassium-competitive acid blocker (PCAB) test can guide treatment of adults with typical reflux symptoms as effectively as standard physiologic testing with endoscopy and 24-hour pH-impedance monitoring. It will also learn about the safety of PCAB-guided management. The main questions it aims to answer are:
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
March 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
March 18, 2026
Actual (reported)June 21, 2026
Actual (reported)July 16, 2026
Actual (reported)March 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
March 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Proportion of Participants with Clinical Response to Treatment
To compare the proportion of participants with typical gastroesophageal reflux disease (GERD) symptoms who achieve a clinical response to treatment. This will be compared between the group receiving treatment guided by the PCAB (Potassium-Competitive Acid Blocker) test and the group receiving treatment guided by physiological testing.
4 weeks
Diagnostic Performance of the PCAB Test for Pathologic Acid Reflux
Baseline
Change in GERD Symptom Severity (Likert Scale)
Baseline and at 4 weeks
Change in Reflux Disease Questionnaire (RDQ) Score
Baseline and at 4 weeks
Percentage of Symptom-Free Days
Up to 4 weeks
Frequency of Rescue Antacid Use
Up to 4 weeks
All patients assigned in PCAB-test guide group will receive esophagodeuodenoscopy, 24-hr pH and impedance monitoring then Vonoprazan 20 mg orally twice daily was prescribed for 7 days.
All patients assigned in Physiologic-test guided group will receive esophagodeuodenoscopy, 24-hr pH and impedance monitoring.
All participants in PCAB-test guided group will receive vonoprazan 20 mg orally twice daily for 7 days
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Faculty of Medicine Siriraj Hospital, Mahidol University
Bangkok Noi, Bangkok, 10700, Thailand
Nasseri-Moghaddam S, Razjouyan H, Nouraei M, Alimohammadi M, Mamarabadi M, Vahedi H, Pourshams A, Mohamadnejad M, Zamani F, Sadr F, Darvish-Moghaddam S, Farsi P, Malekzadeh R. Inter- and intra-observer variability of the Los Angeles classification: a reassessment. Arch Iran Med. 2007 Jan;10(1):48-53.
Dong P, Lin L, Sun K, Tang F, Li Q, Zhou X, Liu F, Yang Z, Li J, Jiang L, Zhao P, Sun X, Wang Q. Accuracy of the diagnosis of gastroesophageal reflux disease by a trial of potassium-competitive acid blocker treatment. BMC Gastroenterol. 2025 May 26;25(1):406. doi: 10.1186/s12876-025-03981-1.
Monthira Maneerattanaporn, MD
Mahidol University
Somchai Leelakusolvong, MD
Mahidol University
Tanawat Geeratragool, MD
Mahidol University
Siwakan Phuetphaichit, MD
Mahidol University
First Submitted
June 21, 2026
First Posted
Contact the study team to confirm eligibility.
Dickman R, Maradey-Romero C, Fass R. The role of pain modulators in esophageal disorders - no pain no gain. Neurogastroenterol Motil. 2014 May;26(5):603-10. doi: 10.1111/nmo.12339.
Shah ED, Gyawali CP, Chan WW. Optimizing the Cost-Effective Evaluation of Gastroesophageal Reflux by Typical Symptom Phenotypes After Failure of Empiric Acid Suppression Trial. Am J Gastroenterol. 2026 Mar 1;121(3):635-648. doi: 10.14309/ajg.0000000000003576. Epub 2025 Jun 5.
Otake K, Sakurai Y, Nishida H, Fukui H, Tagawa Y, Yamasaki H, Karashima M, Otsuka K, Inatomi N. Characteristics of the Novel Potassium-Competitive Acid Blocker Vonoprazan Fumarate (TAK-438). Adv Ther. 2016 Jul;33(7):1140-57. doi: 10.1007/s12325-016-0345-2. Epub 2016 Jun 10.
Oshima T, Miwa H. Potent Potassium-competitive Acid Blockers: A New Era for the Treatment of Acid-related Diseases. J Neurogastroenterol Motil. 2018 Jul 30;24(3):334-344. doi: 10.5056/jnm18029.
Rawla P, Sunkara T, Ofosu A, Gaduputi V. Potassium-competitive acid blockers - are they the next generation of proton pump inhibitors? World J Gastrointest Pharmacol Ther. 2018 Dec 13;9(7):63-68. doi: 10.4292/wjgpt.v9.i7.63.
Numans ME, Lau J, de Wit NJ, Bonis PA. Short-term treatment with proton-pump inhibitors as a test for gastroesophageal reflux disease: a meta-analysis of diagnostic test characteristics. Ann Intern Med. 2004 Apr 6;140(7):518-27. doi: 10.7326/0003-4819-140-7-200404060-00011.
Dickman R, Emmons S, Cui H, Sewell J, Hernandez D, Esquivel RF, Fass R. The effect of a therapeutic trial of high-dose rabeprazole on symptom response of patients with non-cardiac chest pain: a randomized, double-blind, placebo-controlled, crossover trial. Aliment Pharmacol Ther. 2005 Sep 15;22(6):547-55. doi: 10.1111/j.1365-2036.2005.02620.x.
Bautista J, Fullerton H, Briseno M, Cui H, Fass R. The effect of an empirical trial of high-dose lansoprazole on symptom response of patients with non-cardiac chest pain--a randomized, double-blind, placebo-controlled, crossover trial. Aliment Pharmacol Ther. 2004 May 15;19(10):1123-30. doi: 10.1111/j.1365-2036.2004.01941.x.
Xia HH, Lai KC, Lam SK, Hu WH, Wong NY, Hui WM, Lau CP, Chen WH, Chan CK, Wong WM, Wong BC. Symptomatic response to lansoprazole predicts abnormal acid reflux in endoscopy-negative patients with non-cardiac chest pain. Aliment Pharmacol Ther. 2003 Feb;17(3):369-77. doi: 10.1046/j.1365-2036.2003.01436.x.
Pandak WM, Arezo S, Everett S, Jesse R, DeCosta G, Crofts T, Gennings C, Siuta M, Zfass A. Short course of omeprazole: a better first diagnostic approach to noncardiac chest pain than endoscopy, manometry, or 24-hour esophageal pH monitoring. J Clin Gastroenterol. 2002 Oct;35(4):307-14. doi: 10.1097/00004836-200210000-00006.
Juul-Hansen P, Rydning A, Jacobsen CD, Hansen T. High-dose proton-pump inhibitors as a diagnostic test of gastro-oesophageal reflux disease in endoscopic-negative patients. Scand J Gastroenterol. 2001 Aug;36(8):806-10. doi: 10.1080/003655201750313315.
Schindlbeck NE, Klauser AG, Voderholzer WA, Muller-Lissner SA. Empiric therapy for gastroesophageal reflux disease. Arch Intern Med. 1995 Sep 11;155(16):1808-12.
Fass R, Ofman JJ, Gralnek IM, Johnson C, Camargo E, Sampliner RE, Fennerty MB. Clinical and economic assessment of the omeprazole test in patients with symptoms suggestive of gastroesophageal reflux disease. Arch Intern Med. 1999 Oct 11;159(18):2161-8. doi: 10.1001/archinte.159.18.2161.
Johnsson F, Weywadt L, Solhaug JH, Hernqvist H, Bengtsson L. One-week omeprazole treatment in the diagnosis of gastro-oesophageal reflux disease. Scand J Gastroenterol. 1998 Jan;33(1):15-20. doi: 10.1080/00365529850166149.
Bate CM, Riley SA, Chapman RW, Durnin AT, Taylor MD. Evaluation of omeprazole as a cost-effective diagnostic test for gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 1999 Jan;13(1):59-66. doi: 10.1046/j.1365-2036.1999.00429.x.
Schenk BE, Kuipers EJ, Klinkenberg-Knol EC, Festen HP, Jansen EH, Tuynman HA, Schrijver M, Dieleman LA, Meuwissen SG. Omeprazole as a diagnostic tool in gastroesophageal reflux disease. Am J Gastroenterol. 1997 Nov;92(11):1997-2000.
Fass R, Fennerty MB, Ofman JJ, Gralnek IM, Johnson C, Camargo E, Sampliner RE. The clinical and economic value of a short course of omeprazole in patients with noncardiac chest pain. Gastroenterology. 1998 Jul;115(1):42-9. doi: 10.1016/s0016-5085(98)70363-4.
Gyawali CP, Yadlapati R, Fass R, Katzka D, Pandolfino J, Savarino E, Sifrim D, Spechler S, Zerbib F, Fox MR, Bhatia S, de Bortoli N, Cho YK, Cisternas D, Chen CL, Cock C, Hani A, Remes Troche JM, Xiao Y, Vaezi MF, Roman S. Updates to the modern diagnosis of GERD: Lyon consensus 2.0. Gut. 2024 Jan 5;73(2):361-371. doi: 10.1136/gutjnl-2023-330616.
Fass R. Erosive esophagitis and nonerosive reflux disease (NERD): comparison of epidemiologic, physiologic, and therapeutic characteristics. J Clin Gastroenterol. 2007 Feb;41(2):131-7. doi: 10.1097/01.mcg.0000225631.07039.6d.
Kang SJ, Jung HK, Tae CH, Kim SY, Lee KJ. On-demand Versus Continuous Maintenance Treatment of Gastroesophageal Reflux Disease With Proton Pump Inhibitors: A Systematic Review and Meta-analysis. J Neurogastroenterol Motil. 2022 Jan 30;28(1):5-14. doi: 10.5056/jnm21095.
Scarpignato C, Pelosini I. Review article: the opportunities and benefits of extended acid suppression. Aliment Pharmacol Ther. 2006 Jun;23 Suppl 2:23-34. doi: 10.1111/j.1365-2036.2006.02945.x.
Robinson M, Sahba B, Avner D, Jhala N, Greski-Rose PA, Jennings DE. A comparison of lansoprazole and ranitidine in the treatment of erosive oesophagitis. Multicentre Investigational Group. Aliment Pharmacol Ther. 1995 Feb;9(1):25-31. doi: 10.1111/j.1365-2036.1995.tb00347.x.
Patcharatrakul T, Gonlachanvit S. Gastroesophageal reflux symptoms in typical and atypical GERD: roles of gastroesophageal acid refluxes and esophageal motility. J Gastroenterol Hepatol. 2014 Feb;29(2):284-90. doi: 10.1111/jgh.12347.
Moayyedi P, Axon AT. The usefulness of the likelihood ratio in the diagnosis of dyspepsia and gastroesophageal reflux disease. Am J Gastroenterol. 1999 Nov;94(11):3122-5. doi: 10.1111/j.1572-0241.1999.01502.x.
Fass R, Shapiro M, Dekel R, Sewell J. Systematic review: proton-pump inhibitor failure in gastro-oesophageal reflux disease--where next? Aliment Pharmacol Ther. 2005 Jul 15;22(2):79-94. doi: 10.1111/j.1365-2036.2005.02531.x.
Richter JE, Kahrilas PJ, Johanson J, Maton P, Breiter JR, Hwang C, Marino V, Hamelin B, Levine JG; Esomeprazole Study Investigators. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial. Am J Gastroenterol. 2001 Mar;96(3):656-65. doi: 10.1111/j.1572-0241.2001.3600_b.x.
Fass R, Sifrim D. Management of heartburn not responding to proton pump inhibitors. Gut. 2009 Feb;58(2):295-309. doi: 10.1136/gut.2007.145581.
Chiba N, De Gara CJ, Wilkinson JM, Hunt RH. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology. 1997 Jun;112(6):1798-810. doi: 10.1053/gast.1997.v112.pm9178669.
Hershcovici T, Fass R. Nonerosive Reflux Disease (NERD) - An Update. J Neurogastroenterol Motil. 2010 Jan;16(1):8-21. doi: 10.5056/jnm.2010.16.1.8. Epub 2010 Jan 31.
de Bortoli N, Martinucci I, Savarino E, Bellini M, Bredenoord AJ, Franchi R, Bertani L, Furnari M, Savarino V, Blandizzi C, Marchi S. Proton pump inhibitor responders who are not confirmed as GERD patients with impedance and pH monitoring: who are they? Neurogastroenterol Motil. 2014 Jan;26(1):28-35. doi: 10.1111/nmo.12221. Epub 2013 Aug 29.
Weijenborg PW, Cremonini F, Smout AJ, Bredenoord AJ. PPI therapy is equally effective in well-defined non-erosive reflux disease and in reflux esophagitis: a meta-analysis. Neurogastroenterol Motil. 2012 Aug;24(8):747-57, e350. doi: 10.1111/j.1365-2982.2012.01888.x. Epub 2012 Feb 6.
Metz DC, Howden CW, Perez MC, Larsen L, O'Neil J, Atkinson SN. Clinical trial: dexlansoprazole MR, a proton pump inhibitor with dual delayed-release technology, effectively controls symptoms and prevents relapse in patients with healed erosive oesophagitis. Aliment Pharmacol Ther. 2009 Apr 1;29(7):742-54. doi: 10.1111/j.1365-2036.2009.03954.x. Epub 2009 Feb 7.
Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R; Global Consensus Group. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol. 2006 Aug;101(8):1900-20; quiz 1943. doi: 10.1111/j.1572-0241.2006.00630.x.
July 16, 2026
Study Start
March 18, 2026
Actual (reported)Primary Completion
March 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
March 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
July 16, 2026
Record last verified: 2026-07
To protect participant confidentiality and comply with institutional and regulatory requirements, no IPD will be shared unless with reasonable request.
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: